BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.
| Product | Description | |
|---|---|---|
| Biochanin A b-D-glucuronide | Biochanin A b-D-glucuronide is an esteemed compound, acting as a glucuronide conjugate of Biochanin A, an innate isoflavone sourced from botanical entities. Embracing an antioxidative nature, Biochanin A b-D-glucuronide reigns supreme for its anti-mutagenic as well as estrogenic attributes. Synonyms: Biochanin a 7-glucuronide; 38482-76-7; Biochanin A-7-O-beta-D-glucuronide; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-3-(4-methoxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid; Biochanin A beta-D-glucuronide; CHEBI:189737; MFCD31811654; (2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid. CAS No. 38482-76-7. Molecular formula: C22H20O11. Mole weight: 460.39. |  |
| Biricodar Dicitrate | Biricodar Dicitrate is the dicitrate salt form of Biricodar. Biricodar, also known as VX-710 or INCEL, is a novel compound that binds directly to P-gp. VX-710 concentrations of 0.5 to 2.5 M are sufficient to fully restore sensitivity of P-gp expressing cells to the cytotoxic action of paclitaxel and other cytotoxic drugs associated with the MDR phenotype. Synonyms: VX 710-3; (S)-1,7-di(pyridin-3-yl)heptan-4-yl 1-(2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate dicitrate. CAS No. 174254-13-8. Molecular formula: C46H57N3O21. Mole weight: 987.96. | |
| Bis-(5-aldo-1,2-O-isopropylidene-D-xylo-pentofuranose) 5,5:3,5-Cyclic acetal | Bis-(5-aldo-1,2-O-isopropylidene-D-xylo-pentofuranose) 5,5:3,5-Cyclic acetal is an indispensable element in the biomedical field, serving as a pivotal player in the development of antiviral pharmaceuticals. Synonyms: 5-aldo-1,2-O-isopropylidene-D-xylo-pentofuranose dimer; 1,2-O-Isopropylidene-α-D-xylo-pentodialdo-1,4-furanose dimer. | |
| Bismuth Subcitrate Potassium | Bismuth Subcitrate is an antibiotic used to treat stomach ulcers associated with Helicobacter pylori, a bacterial infection. Synonyms: Bismuth(III) pentapotassium 2-oxidopropane-1,2,3-tricarboxylate. Grades: >98%. CAS No. 880149-29-1. Molecular formula: C12H16BiK5O14. Mole weight: 788.72. | |
| Bitopertin | Bitopertin is a potent and noncompetitive glycine reuptake inhibitor (GlyT1). It is effective in reducing the negative symptoms when given in combination with second generation antipsychotics. It is currently in Phase III trials for the treatment of the negative symptoms of schizophrenia. Synonyms: RG-1678; RG1678; RG 1678; R-1678; R1678; R 1678; RO4917838; RO-4917838; RO 4917838; Bitopertin. Grades: >98%. CAS No. 845614-11-1. Molecular formula: C21H20F7N3O4S. Mole weight: 543.46. | |
| Bitopertin R enantiomer | Bitopertin R enantiomer is the R enantiomer of Bitopertin, which is a potent and noncompetitive glycine reuptake inhibitor (GlyT1). Synonyms: RG1678 (R enantiomer); RG 1678 (R enantiomer); RG-1678 (R enantiomer); RO4917838 (R enantiomer). Grades: >98%. CAS No. 845614-12-2. Molecular formula: C21H20F7N3O4S. Mole weight: 543.46. | |
| BIX 01294 trihydrochloride | BIX 01294 is a G9a histone methyltransferase inhibitor. It enhances the induction of pluripotent stem cells from somatic cells in vitro. BIX-01294 trihydrochloride induces necroptosis and autophagy. Synonyms: BIX 01294 trihydrochloride; BIX-01294; N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine trihydrochloride. Grades: >98%. CAS No. 1392399-03-9. Molecular formula: C28H41Cl3N6O2. Mole weight: 600.02. | |
| BIX 02189 | BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2. Synonyms: BIX02189; BIX-02189; (Z)-3- ( (3- ( (dimethylamino)methyl)phenylamino) (phenyl)methylene)-N, N-dimethyl-2-oxoindoline-6-carboxamide. Grades: >98%. CAS No. 1094614-85-3. Molecular formula: C27H28N4O2. Mole weight: 440.54. | |
| Bizelesin | Bizelesin is a synthetic cyclopropylpyrroloindole antineoplastic antibiotic. Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis. Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. Uses: Antineoplastic agents, alkylating. Synonyms: U-77779; U 77779; U77779; NSC-615291; N,N'-Bis[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]urea. CAS No. 129655-21-6. Molecular formula: C43H36Cl2N8O5. Mole weight: 815.71. | |
| BJB-2936 | BJB-2936 is a novel inhibitor of FBPase 1, which plays a role in gluconeogenesis. Study showed that in KKAgamma and db/db mouse model, BJB-2936 significantly decreased the level of glucose and HbA1c. BJB-2936 is promisingly developed to be a drug for diabetes. Uses: The potential treatment of diabetes. Synonyms: BJB 2936; BJB2936. | |
| b-L-Arabinopyranose | b-L-Arabinopyranose is a fundamental component employed extensively in the manufacture of antiviral pharmaceuticals, serving as a pivotal cornerstone in studying diverse bacterial and fungal infections. Its utilization frequently accompanies nucleoside analogs to facilitate the research of ailments like HIV and herpes. Synonyms: beta-L-Arabinose; beta-L-Arabinopyranose; 7296-56-2; b-L-Arabinopyranose; (2S,3R,4S,5S)-oxane-2,3,4,5-tetrol.beta.-L-Arabinopyranose; 194RG7YBRS; L(+)-Arabinose; (2S,3R,4S,5S)-tetrahydro-2H-pyran-2,3,4,5-tetraol; 87-72-9; Pentopyranose #; alpha-L-Arabinose; ARB; Arabinopyranose, beta-L-; UNII-194RG7YBRS; Arabinopyranose. beta.-L-; 1bap; 3tb6; beta-L-(+)-Arabinose; bmse000213.BETA.-L-ARABINOSE; SCHEMBL4430971; CHEBI:40886; SRBFZHDQGSBBOR-KLVWXMOXSA-N; DTXSID201315644; MFCD00067709; s3986; AKOS025402335; AC-8171; CCG-266201; NCGC00160355-01; C02479; Q27120409; F0F57802-D37D-4858-8FE9-F695304211C1. CAS No. 7296-56-2. Molecular formula: C5H10O5. Mole weight: 150.1. | |
| b-L-Arabinose-1-phosphate | b-L-Arabinose-1-phosphate is an essential intermediate engaged in diverse biochemical processes assuming the position of a fundamental substrate to facilitative enzymes accountable for the intricate metabolism of arabinose. | |
| b-L-Fucopyranosylamine | b-L-Fucopyranosylamine is an indispensable compound, used for studying a myriad of ailments, encompassing cancer and autoimmune disorders. Deemed exceptional due to its distinctive attributes, this compound showcases immense efficacy in selectively studying aberrant cell proliferation, while concurrently modulating the intricate immune response. Synonyms: 2-amino-6-methyloxane-3,4,5-triol; B-l-fucopyranosylamine; 103419-79-0; SCHEMBL22779020; AKOS030241001; FT-0668893. CAS No. 103419-79-0. Molecular formula: C6H13NO4. Mole weight: 163.17. | |
| b-L-Fucopyranosyl nitromethane | b-L-Fucopyranosyl nitromethane is a paramount biomedical compound, standing as a resolute weapon to study a diverse spectrum of afflictions encompassing malignancy and inflammatory disorders. Synonyms: 2,6-Anhydro-1,7-dideoxy-7-nitro-D-glycero-D-galacto-heptitol. Molecular formula: C7H13NO6. Mole weight: 207.2. | |
| b-L-Glucose-1-phosphate ammonium salt | b-L-Glucose-1-phosphate ammonium salt is an indispensable compound fundamental to the research of diverse disorders pertaining to glucose metabolism, encompassing glycogen storage diseases and diabetes. By serving as a synthetic predecessor, it facilitates the compoundion of glucose-1-phosphate is an imperatively significant molecule intricately entwined with glycogen research and development and subsequent energy storage. Molecular formula: C6H19N2O9P. Mole weight: 294.20. | |
| blinatumomab | Blinatumomab is a monoclonal antibody used for the treatment of Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It effects against tumor cells via binding to a CD3 site for T cells and a CD19 site for the target B cells, which express both in pediatric and adult populations. Uses: The treatment of philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. Synonyms: Blincyto. CAS No. 853426-35-4. Molecular formula: C2367H3577N649O772S19. Mole weight: 54100. | |
| Blosozumab | Blosozumab is a recombinant monoclonal antibody binding to sclerostin (SOST). Blosozumab could be used as a target drug to improve bone mineral density in postmenopausal women. Synonyms: LY2541546; LY-2541546; LY 2541546. CAS No. 1132758-87-2. | |
| b-L-Rhamnopyranosyl nitromethane | b-L-Rhamnopyranosyl nitromethane is a highly versatile and extensively researched compound in the realm of biomedicine. Its impressive therapeutic prospects make it a compelling candidate for combating various ailments, such as cancer and inflammatory disorders. Synonyms: 2,6-Anhydro-1,7-dideoxy-1-nitro-L-glycero-L-galacto-heptitol. CAS No. 30627-99-7. Molecular formula: C7H13NO6. Mole weight: 207.18. | |
| Blue dextran (MW 2000000) - from Leuconostoc spp | Blue dextran (MW 2000000) from Leuconostoc spp is an intriguing biomaterial that serves as a vital instrument in the realm of biomedical research. This dye-conjugated polysaccharide, renowned for its extensive molecular dimensions, is ubiquitously employed as a discerning gauge and meticulous exploring agent within the realms of molecular weight ascertainment, gel filtration chromatography, and the profound investigation of vascular permeability. The compound is pharmacologically active and could advance drug research into diseases such as cancer, cardiovascular disease and kidney disease. Synonyms: Blue Dextran 5. CAS No. 87915-38-6. Molecular formula: (C6H10O5)n. | |
| BMH-21 | BMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription. Uses: Enzyme inhibitors. Synonyms: BMH-21; BMH 21; BMH21. Grades: >98%. CAS No. 896705-16-1. Molecular formula: C21H22N4O2. Mole weight: 362.43. | |
| BMI-1026 | BMI-1026 is an exceedingly potent and remarkably selective inhibitor utilized in the biomedical sector, specifically zeroes in on the intricate signalling pathway of interleukin-1 receptor-associated kinase 4 (IRAK-4). Synonyms: BMI 1026; BMI1026; 4-(2-Aminopyrimidin-4-yl)-6-(2-aminopyrimidin-4(3H)-ylidene)cyclohexa-2,4-dien-1-one. Grades: >98%. CAS No. 477726-77-5. Molecular formula: C34H60N3O7PS. Mole weight: 280.29. | |
| BML-244 | BML-244 is a potent cathespin K inhibitor. Synonyms: BML 244; BML244; (1-formyl-pentyl)-carbamic acid tert-butyl ester; 2-[(tert-Butyloxycarbonyl)amino]hexanal. Grades: 98%. CAS No. 104062-70-6. Molecular formula: C11H21NO3. Mole weight: 215.29. | |
| BML-258 HCl | Cas No. 1072443-89-0. | |
| BMS-002 | BMS-002 is a selective antogonist of lysophosphatidic acid (LPA) receptor-1 developed to treat diabetic nephropathy. In eNOS-/- db/db mouse model, BMS-002 significantly decreased the level of proteinuria. Uses: The potential treatment of diabetic nephropathy. Synonyms: BMS 002; BMS002. | |
| BMS-186511 | BMS-186511 is a Farnesyltransferase (FT) inhibitor with potential anticancer activity. Synonyms: BMS186511; BMS 186511; ((5S,8S,11S)-8,11-diisopropyl-5-(methoxycarbonyl)-7,10,13-trioxo-2-thia-6,9,12-triazapentadecan-15-yl)((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)phosphinic acid. Grades: >98%. CAS No. 167467-53-0. Molecular formula: C26H27N5O5. Mole weight: 685.90. | |
| BMS-193885 salt | BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50=5.9nM, Ki=3.3 nM. BMS-193885 displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over σ1, α1, Y2, Y4 and Y5 receptors respectively. Synonyms: BMS 193885; BMS193885; 1, 4-dihydro-4- [3- [ [ [ [3- [4- (3-methoxyphenyl) -1-piperidinyl] propyl] amino] carbonyl] amino] phenyl] -2, 6-dimethyl-3, 5-dimethyl ester-3,5-pyridinedicarboxylic acid. Grades: >98%. CAS No. 679839-66-8. Molecular formula: C36H48N4O9. Mole weight: 680.79. | |
| BMS-212 | BMS-212 is a potent and selective stimulator of glucokinase (GK) (EC50 = 35 nM) that is promisingly used as an antidiabetic. BMS-212 has a preference for GK in liver over GK in pancreas, of which the activation may lead to non-glucose-dependent insulin secretion. Half-life of BMS-212 is 4.2h, and oral bioavailability is 15%. Uses: Potential antidiabetic. Synonyms: BMS212; BMS 212. CAS No. 2173153-38-1. Molecular formula: C25H30N3O9PS2. Mole weight: 611.62. | |
| BMS-214662 | BMS-214662 is a Farnesyltransferase inhibitor and a nonsedating benzodiazepine derivative with potential antineoplastic activity. BMS-214662 inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. Synonyms: BMS 214662; BMS214662; ARQ-171; ARQ 171; ARQ171; (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile. Grades: 98%. CAS No. 195987-41-8. Molecular formula: C25H23N5O2S2. Mole weight: 489.61. | |
| BMS-275183 | BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action, stabilization of tubulin polymerization. BMS-275183 given p.o. was active in a human, hormone-dependent, prostate tumor model, CWR-22, and just as effective as anti-androgen chemotherapy. BMS-275185 is lack of evidence of clinical benefit with the occurrence of two fatal events of neutropenic sepsis. Synonyms: BMS 275183; BMS275183. CAS No. 355113-98-3. Molecular formula: C43H59NO16. Mole weight: 845.94. | |
| BMS-284640 | BMS-284640 is a Na(+)/H(+) exchanger (NHE) inhibitor developed for the treatment of cardiovascular therapies. Synonyms: BMS 284640; BMS284640; N-[(1R,3R)-3-(2,3-Dihydro-benzofuran-4-yl)-2,2-dimethyl-cyclopropanecarbonyl]-guanidine. Grades: >98%. CAS No. 230640-88-7. Molecular formula: C15H19N3O2. Mole weight: 273.33. | |
| BMS-3 | BMS-3, a LIMK1 inhibitor, could be probably influence the migration and cycle progression of cells so that has patential value in studying its effect against cancer. Synonyms: N-(5-(1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)cyclopropanecarboxamide; BMS3; BMS 3; Cyclopropanecarboxamide, N-[5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-; N-{5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-1,3-thiazol-2-yl}cyclopropanecarboxamide. Grades: 95%. CAS No. 1338247-30-5. Molecular formula: C17H12Cl2F2N4OS. Mole weight: 429.27. | |
| BMS-317180 | BMS-317180 is a potent, and orally effective growth hormone secretagogue (GHS) that shows an excellent safety profile in preclinical studies. Synonyms: BMS317180; BMS 317180; (S)-2-(5-(1-(2-amino-2-methylpropanamido)-2-(benzyloxy)ethyl)-1H-tetrazol-1-yl)ethyl (4-hydroxybutyl)carbamate. Grades: >98%. CAS No. 295337-71-2. Molecular formula: C26H30N5O2P. Mole weight: 463.54. | |
| BMS-337197 | BMS-337197 is a a potent inhibitor of IMPDH with potential anticancer activity. Synonyms: BMS 337197; BMS337197; N-(2-(2-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)oxazol-5-yl)phenyl)-N-methyl-2-morpholinoacetamide. Grades: >98%. CAS No. 267645-83-0. Molecular formula: C24H34N5OP. Mole weight: 489.53. | |
| BMS-351 | BMS-351 is a selective and nonsteroidal CYP17A1 lyase inhibitor with good selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 has become a preclinical candidate to treat Castration-resistant prostate cancer (CRPC) and is likely to minimize the side effects of current therapies because of its exceptional selectivity. Uses: Castration-resistant prostate cancer. Synonyms: BMS-351; BMS 351; BMS351; 4-(4-methylpyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazole. Grades: 98%. CAS No. 1370001-71-0. Molecular formula: C15H12F3N3. Mole weight: 291.28. | |
| BMS358233 | BMS358233 is a potent Lck inhibitor. It has excellent cellular activities against T-cell proliferation. Uses: Bms358233 has excellent cellular activities against t-cell proliferation. Synonyms: BMS-358233; BMS 358233; 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-methyl-2-((((2R)-tetrahydro-2-furanyl)methyl)amino)-4-pyrimidinyl)amino)-. Grades: 98%. CAS No. 601519-75-9. Molecular formula: C25H25ClN6O2S. Mole weight: 509.02. | |
| BMS480404 | BMS480404 is a potent small molecule inhibitor. It bounds to human keratinocyte fatty acid-binding protein. Synonyms: BMS-480404; BMS 480404; (S)-2-(2,3-bis(2-chlorobenzyloxy)phenyl)-2-hydroxyacetic acid. Grades: 98%. CAS No. 533889-36-0. Molecular formula: C22H18Cl2O5. Mole weight: 433.28. | |
| BMS-5 | BMS-5, a LIMK inhibitor, has been found to restrain the cofilin phosphorylation in MDA-MB-231 breast cancer cells. Synonyms: LIMKi 3; N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide; N-{5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-1,3-thiazol-2-yl}-2-methylpropanamide; BMS 5; BMS5. Grades: 98%. CAS No. 1338247-35-0. Molecular formula: C17H14Cl2F2N4OS. Mole weight: 431.29. | |
| BMS538158 | BMS538158 is a bio-active chemical compound developed by Bristol-Myers Squibb. Synonyms: BMS-538158; BMS 538158; Acetamide, 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-N-((4-fluorophenyl)methyl)-N-methoxy-. Grades: 98%. CAS No. 543730-36-5. Molecular formula: C15H16FNO5. Mole weight: 309.29. | |
| BMS-566419 | Potent inosine monophosphate dehydrogenase (IMPDH) inhibitor (IC50 = 17 nM). Inhibits proliferation of human T-lymphoblasts and PBMCs in vitro. Reduces paw swelling in a rat adjuvant arthritis model. Synonyms: BMS 566419; BMS566419; N-(1-(6-(4-Ethyl-1-piperazinyl)-3-pyridinyl)-1-methylethyl)-2-fluoro-9,10-dihydro-9-oxo-3-acridinecarboxamide. Grades: >98%. CAS No. 566161-24-8. Molecular formula: C28H30FN5O2. Mole weight: 487.57. | |
| BMS-593214 | BMS-593214 is an active-site, direct FVIIa inhibitor. It displayed direct, competitive inhibition of human FVIIa in the hydrolysis of a tripeptide substrate with Ki of 5 nM. Synonyms: BMS593214; BMS 593214; 2'-(2-Carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5'-hydroxy-4'-methoxy-biphenyl-4-carboxylic acid. Grades: >98%. CAS No. 1004551-40-9. Molecular formula: C31H27N3O4. Mole weight: 505.56. | |
| BMS639623 | BMS639623 is a CCR3 antagonist with picomolar inhibition potency against eosinophil chemotaxis. It may be used for the treatment of asthma. Uses: Bms639623 may be used for the treatment of asthma. Synonyms: BMS-639623; BMS 639623; Urea, N-((1R,2S)-3-((3S)-3-((4-fluorophenyl)methyl)-1-piperidinyl)-2-hydroxy-1-methylpropyl)-N'-(3-(1-methyl-1H-tetrazol-5-yl)phenyl)-. Grades: 98%. CAS No. 675122-44-8. Molecular formula: C25H32FN7O2. Mole weight: 481.57. | |
| BMS-641988 | BMS-641988 is a nonsteroidal androgen receptor (AR) antagonist with anti-androgenic and potential antineoplastic activities. BMS-641988 binds to ARs in target tissues and prevents AR activation, which may result in the inhibition of AR-mediated transcriptional activity and tumor cell death in susceptible tumor cell populations. Synonyms: BMS641988; BMS 641988; Ethanesulfonamide, N-((3aR,4R,5R,7R,7aS)-2-(4-cyano-3-(trifluoromethyl)phenyl)octahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-1H-isoindol-5-yl)-. CAS No. 573738-99-5. Molecular formula: C20H20F3N3O5S. Mole weight: 471.45. | |
| BMS-645737 | BMS-645737 is an inhibitor of vascular endothelial growth factor (VEGF) receptor-2 and fibroblast growth factor (FGF) receptor-1. BMS-646737 has anti-angiogenic activity and was evaluated in nonclinical studies as a treatment for cancer. Synonyms: BMS645737; BMS 645737; 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine. Grades: >98%. CAS No. 651744-16-0. Molecular formula: C20H20N8O. Mole weight: 388.43. | |
| BMS694153 | BMS694153 is a potent and selective calcitonin gene-related peptide(CGRP) receptor antagonist. It is related with the pathogenesis of migraine. Uses: Bms694153 is related with the pathogenesis of migraine. Synonyms: BMS-694153; BMS 694153; BMS694153; (R)-N-(1-([1,4'-bipiperidin]-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(8-fluoro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide;(R)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide;4-(8-Fluoro-2-oxo-1,4-dihydroquinazolin-3-yl)-N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-piperidin-1-ylpiperidin-1-yl)propan-2-yl]piperidine-1-carboxamide. Grades: >98 %. CAS No. 1050381-35-5. Molecular formula: C35H45FN8O3. Mole weight: 644.79. | |
| BMS-833923 | BMS-833923 is an orally bioavailable small-molecule Smo (Smoothened) inhibitor with potential antineoplastic activity. It inhibits the sonic hedgehog (shh) pathway protein Smo, which may result in suppression of shh signaling pathway. Synonyms: BMS 833923; XL139; N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide. Grades: >98%. CAS No. 1059734-66-5. Molecular formula: C30H27N5O. Mole weight: 473.57. | |
| BMS-856 | BMS-856 shows low nanomolar inhibition of 17beta-HSD3 enzymatic activity. It displays inhibition of 17beta-HSD3-mediated cellular conversion of AdT to testosterone and inhibits the 17beta-HSD3-mediated conversion of testosterone necessary to promote AR-dependent transcription. BMS-856 can be used for endocrine therapy of prostate cancer. Uses: Endocrine therapy of prostate cancer. Synonyms: BMS 856; BMS856; UNII-7IQ5DK4G01; 7IQ5DK4G01; 2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-Benzamide. Grades: 98%. CAS No. 863382-83-6. Molecular formula: C29H25ClN2O5. Mole weight: 516.97. | |
| BMS-863233 HCl | BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BMS-863233; BMS863233; BMS 863233; XL-413; XL413; XL 413. CAS No. 1169562-71-3. Molecular formula: C14H13Cl2N3O2. Mole weight: 289.72. | |
| BMS-906024 | BMS-906024, a selective and orally active γ-secretase inhibitor, is a potent inhibitor of pan-Notch receptors with IC50s of 1.6, 0.7, 3.4 and 2.9 nM for Notch-1, -2, -3 and -4 receptors, respectively. It has broad-spectrum antineoplastic activity. Synonyms: (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; NSC-780812; Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-. Grades: ≥98%. CAS No. 1401066-79-2. Molecular formula: C26H26F6N4O3. Mole weight: 556.50. | |
| BMS986195 R-isomer | An R isomer of BMS-986195, a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Synonyms: (R)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; (R)-Branebrutinib; (R)-BMS-986195. CAS No. 1912445-70-5. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMX-IN-1 | BMX-IN-1 selectively and irreversibly inhibits BMX (IC50=8nM) that is significant for ischemia-mediated arteriogenesis and lymphangiogenesis regulation. It also inhibits the proliferation of RV-1 (GI50s=2.54μM), DU-145 (GI50s=4.38μM), PC-3 (GI50s=5.37nM). Synonyms: N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamideBMX-IN-1; BMX-IN1; BMX-IN 1.1431525-23-3GTPL9269SCHEMBL17052523BDBM102620CS-1295; HY-80002; W-6056; CS 1295; HY 80002; W 6056; CS1295; HY80002; W6056Example 1-14 [ WO2014063054]N-[5-[9-[4-(methanesulfonamido)phenyl]. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.59. | |
| Bmy 42393 | BMY-42393 is a selective platelet aggregation inhibitor. It is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation with IC50 value range from 0.3 to 2.0 mM. BMY-42393 can stimulate platelet adenylate cyclase with EC50 value of 25 nM. BMY 42393 can also inhibit thrombin-induced elevation of intracellular free calcium. Research for the treatment of Hyperlipidaemia was discontinued. Uses: Hyperlipidaemia. Synonyms: BMY-42393; BMY 42393; BMY42393. SCHEMBL675089; AC1L304B; CHEMBL117835;2-[3-[2-(4,5-diphenyl-1,3-oxazol-2-yl)ethyl]phenoxy]acetic acid. Grades: 98%. CAS No. 136451-58-6. Molecular formula: C25H21NO4. Mole weight: 399.45. | |
| BMY 7378 | BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. Uses: Adrenergic alpha-antagonists. Synonyms: BMY7378; BMY-7378; 1,1-Cyclopentanediacetimide, N-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-, dihydrochloride; N-(2-(4-(o-Methoxyphenyl)-1-piperazinyl)ethyl)-1,1-cyclopentanediacetimide dihydrochloride. Grades: >98%. CAS No. 21102-95-4. Molecular formula: C22H33Cl2N3O3. Mole weight: 458.42. | |
| BNC105P | BNC105P is a benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BNC105P; BNC 105P; BNC-105P. CAS No. 945771-96-0. Molecular formula: C20H19Na2O10P. Mole weight: 496.32. | |
| Bococizumab | Bococizumab is a humanized monoclonal antibody binding to proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces LDL cholesterol (LDL-C) levels. Bococizumab may be used as a potential drug for the treatment of hypercholesterolemia. Synonyms: PF-04950615; PF 04950615; PF04950615. CAS No. 1407495-02-6. | |
| BOP sodium salt | BOP is a dual α9β1/α4β1 integrin inhibitor preferentially mobilizes HSCs and progenitors. Synonyms: N-(Benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcarbonyl)tyrosine sodium salt. Grades: ≥98% by HPLC. CAS No. 1947348-42-6. Molecular formula: C25H28N3O7SNa. Mole weight: 537.56. | |
| BP-1-102 | BP-1-102 is a potent and selective STAT3 inhibitor. BP-1-102 inhibits the expression of genes including c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8, which is related to the STAT3-mediated breast tumor growth and migration. Synonyms: 4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid. Grades: >98%. CAS No. 1334493-07-0. Molecular formula: C29H27F5N2O6S. Mole weight: 626.595. | |
| BPR1J-340 | BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy. Synonyms: BPR1J 340; BPR1J340. Grades: 98%. CAS No. 1395051-72-5. Molecular formula: C29H34N8O3. Mole weight: 542.63. | |
| BPR1K653 | SBPR1K653 is a potent Aurora kinase inhibitor with potential anticancder activity. BPR1K653 specifically inhibited the activity of Aurora-A and Aurora-B kinase at low nano-molar concentrations in vitro. BPR1K653 was potent in targeting a variety of cancer cell lines regardless of the tissue origin, p53 status, or expression of MDR1. At the cellular level, BPR1K653 induced endo-replication and subsequent apoptosis in both MDR1-negative and MDR1-positive cancer cells. Importantly, it showed potent activity against the growth of xenograft tumors of the human cervical carcinoma KB and KB-derived MDR1-positive KB-VIN10 cells in nude mice. Finally, BPR1K653 also exhibited favorable pharmacokinetic properties in rats., BPR1K653 is a promising anti-cancer compound that has potential for the management of various malignancies, particularly for patients with MDR1-related drug resistance after prolonged chemotherapeutic treatments. Synonyms: BPR1K653; BPR1K 653; BPR1K-653. Grades: 98%. CAS No. 1192754-07-6. Molecular formula: C30H30Cl2N6O2. Mole weight: 541.04. | |
| Brasofensine | Brasofensine is a phenyltropane drug that is developed for the treatment of Parkinson's and Alzheimer's disease. Synonyms: NS-2214; BMS-204756; (E)-1-[(2R,3S)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-N-methoxymethanimine. CAS No. 171655-91-7. Molecular formula: C16H20Cl2N2O. Mole weight: 327.249. | |
| BRD7116 | BRD7116 is an inhibitor of leukemia stem cell (LSC) activity (EC50 = 200 nM) but does not affect normal hematopoietic stem cells or AML cells. Synonyms: BRD-7116; 2, 2, 3, 3-tetramethyl-N- [4- [4- [ (2, 2, 3, 3-tetramethylcyclopropanecarbonyl) amino] phenyl] sulfonylphenyl] cyclopropane-1-carboxamide. Grades: >98%. CAS No. 329059-55-4. Molecular formula: C28H36N2O4S. Mole weight: 496.66. | |
| Brentuximab | Brentuximab is a chimeric antibody directed against CD30, a protein often found at high levels on classical Hodgkin lymphoma cells (called Reed-Sternberg cells). CAS No. 2088770-90-3. | |
| Brequinar | Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Check for active clinical trials or closed clinical trials using this agent. Synonyms: DUP785; NSC 368390; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-; Biphenquinate. Grades: ≥98%. CAS No. 96187-53-0. Molecular formula: C23H15F2NO2. Mole weight: 375.37. | |
| Briciclib | Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells. It is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. It may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. It inhibits the proliferation of MCL, gastric, breast and esophageal cancer cell lines at nanomolar concentrations (GI50 = 9.8 - 12.2 nM) in vitro. It binds to eIF4E, blocking cap-dependent translation of cyclin D1 and other cancer proteins and leads to tumor cell death in vitro. It is active in nonclinical tumor models when combined with several chemotherapeutics. Uses: Briciclib may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. it is active in nonclinical tumor models when combined with several chemotherapeutics. Synonyms: Phenol, 2-Methoxy-5-[[[ (1E) -2- (2, 4, 6-triMethoxyphenyl) ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate);ON-014185;(E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dihydrogen phosphate; [2-methoxy-5-[[ (E) -2- (2, 4, 6-trimethoxyphenyl) ethenyl]sulfonylmethyl]phenyl] dihydrogen phosphate. Grades: >98 %. CAS No. 865783-99-9. Molecular formula: C19H23O10PS. Mole weight: 474.42. | |
| Briciclib sodium | Briciclib, also known as ON 013105 or ON 014185, is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, cyclin D modulator ON 013105 is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis. Synonyms: ON-013105; ON013105; ON 013105; ON 014185; ON014185; ON-014185. Grades: >98%. CAS No. 865784-01-6. Molecular formula: C19H21Na2O10PS. Mole weight: 518.38. | |
| Brodalumab | Brodalumab is a human monoclonal antibody that binds to the interleukin-17 receptor and inhibits the binding of IL-17 to its receptor. Brodalumab has been approved for the treatment of moderate to severe plaque psoriasis. Synonyms: Siliq; Kyntheum; AMG-827; KHK-4827; anti-IL17RA. CAS No. 1174395-19-7. | |
| Bromo-2-tetraacetyl galactose | Bromo-2-tetraacetyl galactose is a profound compound extensively employed in the biomedical sector, serving as a precursor in antivirals research and development and its exploration in carbohydrate metabolism-related ailments render it invaluable. | |
| Bromoconduritol | Bromoconduritol is a widely employed compound assuming a pivotal role in the intricate exploration and development of drugs targeting assorted ailments viz., diabetes, cancer and neurological disorders. Synonyms: 6-Bromo-3,4,5-trihydroxy cyclohex-1-ene; 6-Bromo-4-cyclohexene-1,2,3-triol. CAS No. 42014-74-4. Molecular formula: C6H9O3Br. Mole weight: 209.04. | |
| Bromoxynil 2,3,4-tri-O-acetyl-D-glucuronide methyl ester | Bromoxynil 2,3,4-tri-O-acetyl-D-glucuronide methyl ester is a specialized compound primarily employed in research of the metabolism and toxicity of Bromoxynil, a herbicide widely used in agriculture. It aids in elucidating the biological activities and potential therapeutic effects of Bromoxynil for studying various diseases, including herbicide poisoning or herbicide-induced toxicities. Molecular formula: C20H19Br2NO10. Mole weight: 593.17. | |
| Bromoxynil D-glucuronide methyl ester | Bromoxynil D-glucuronide methyl ester is a noteworthy compound, exhibiting its potential in research of herbicide toxicity arising from bromoxynil. Its role as a metabolite of bromoxynil crucially contributes to the detoxification process and enhances excretion capabilities. Molecular formula: C14H13Br2NO7. Mole weight: 467.06. | |
| Brostallicin hydrochloride | Brostallicin is a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents. Synonyms: PNU-166196; PNU 166196; PNU166196; 4-(2-bromoacrylamido)-N-(5-(5-(5-(2-guanidinoethylcarbamoyl)-1-methyl- 1H-pyrrol-3-ylcarbamoyl)-1-methyl-1H-pyrrol-3-ylcarbamoyl)-1-methyl-1H- pyrrol-3-yl)-1-methyl-1H-pyrrole-2-carboxamide. CAS No. 203258-38-2. Molecular formula: C30H36BrClN12O5. Mole weight: 760.05. | |
Our database is helping our users find suppliers everyday.
